Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inactivated pepsin fraction is an experimental **biologic peptide/protein therapeutic** derived from pepsin and developed by Viral Genetics. It has been described as a modified pepsin-derived fraction with an apparent molecular weight of about 45 kDa, produced by isolating active pepsin and then inactivating and purifying it through pH manipulation, precipitation, and reverse-phase high-pressure liquid chromatography. The proposed mechanism is atypical and incompletely validated, but reported work attributes activity to binding interactions with HIV-1 envelope components including gp120 and gp41, interactions involving CD4-positive cells, and modulation of the heat shock protein gp96, with downstream immunomodulatory and potential antiviral effects. The agent was primarily investigated for HIV/AIDS, with additional exploratory claims in hepatitis, multiple sclerosis, lupus, herpes simplex infection, and cancer-related immune modulation, but no approved product or well-established late-stage development program is evident from the provided context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inactivated pepsin fraction.